Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1244]

Optimal use of asparaginase for acute lymphoblastic leukaemia

Dr Ibrahim Aldoss - City of Hope, Duarte, USA

Optimal use of asparaginase for acute lymphoblastic leukaemia ( Dr Ibrahim Aldoss - City of Hope, Duarte, USA )

Healthcare delivery for non-communicable diseases among breast cancer survivors...

Dr Sanjeeva Gunasekera - National Cancer Institute, Maharagama, Sri Lanka

Healthcare delivery for non-communicable diseases among breast cancer survivors in Sri Lanka: Is there a missed opportunity? ( Dr Sanjeeva Gunasekera - National Cancer Institute, Maharagama, Sri Lanka )

ESMO 2021: Latest in EGFR mutated advanced NSCLC

Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera

ESMO 2021: Latest in EGFR mutated advanced NSCLC ( Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera )

Quality of life and safety in novel therapies for prostate cancer

Prof Heather Payne, Prof Alicia Morgans and Prof Bertrand Tombal

Quality of life and safety in novel therapies for prostate cancer ( Prof Heather Payne, Prof Alicia Morgans and Prof Bertrand Tombal )

[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally...

Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain

[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer ( Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain )

Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal...

Dr Marwan Fakih - City of Hope Comprehensive Cancer Center, Duarte, USA

Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal cancer ( Dr Marwan Fakih - City of Hope Comprehensive Cancer Center, Duarte, USA )

Welcome to APCCC 2021

Prof Silke Gillessen and Prof Aurelius Omlin

Welcome to APCCC 2021 ( Prof Silke Gillessen and Prof Aurelius Omlin )

Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed...

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

$Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed refractory multiple myeloma ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )$

OncoAlert and ecancer - ESMO 2021 Day 5

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 5 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity

Dr Danny Nguyen - City of Hope, Orange County, USA

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity ( Dr Danny Nguyen - City of Hope, Orange County, USA )

CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple...

Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA

CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple myeloma ( Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA )

Impact of cytogenetic abnormalities on treatment outcomes in patients with AL...

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

Impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )

More from ecancer